Streetbeat News

Products Services

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is set to release its Q4 earnings on Feb. 5, 2024, with analysts predicting an EPS of $4.10, up from $3.76 year-over-year, and revenue of $2.51 billion, up from $2.3 billion. The company recently announced positive results from its Phase 3 trials for VX-548. Shares fell 2.1% to $424.68 recently. Analysts from JP Morgan, Truist Securities, Canaccord Genuity, RBC Capital, and HC Wainwright & Co. have updated their ratings and price targets for VRTX.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 3:59 pm

OMIC

Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced at the AGBT conference the unveiling of the G4X Spatial Sequencer, an upgrade to the G4 Sequencing Platform, offering high-throughput in situ spatial sequencing capabilities. The G4X is expected to be available by the end of 2024. Additionally, Singular announced updates to the G4 platform, including a higher-throughput F4 Flow Cell, improved sequencing quality, and a new web-based application for remote monitoring. The company also introduced price reductions and promotional packages for the G4 and G4X, alongside research grant programs.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 3:56 pm

BIDU

Recent analysis of options activity for Baidu (NASDAQ:BIDU) reveals a bearish sentiment among investors, with 75% of trades being puts. The volume and open interest data suggest a price target range of $95.0 to $120.0 for Baidu. The company, a leader in China's internet search market, is also focusing on AI, video streaming, voice recognition, and autonomous driving. Baidu's stock is currently down by -0.31%, trading at $102.47, with an earnings announcement expected in 16 days.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 3:46 pm

UBER

Recent options trading activity indicates a bearish sentiment towards Uber Technologies (NYSE:UBER), with 66% of trades being bearish. The trading volume and open interest analysis suggest a targeted price range of $40.0 to $80.0 for UBER over the last 3 months. The company, a major player in ridesharing and food delivery, operates in over 63 countries. Despite the bearish options sentiment, UBER's stock is slightly up by 0.31%, trading at $68.28. Analysts have set an average price target of $73.0, with ratings ranging from Outperform to Buy.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 3:46 pm

ASML

Financial analysts have observed a bullish trend in options trading for ASML Holding (NASDAQ:ASML), with a significant number of trades indicating a positive outlook. The analysis of 24 unusual trades showed a majority bullish sentiment, with 15 calls valued at $975,946 outperforming 9 puts worth $670,685. The price target for ASML is set between $580.0 and $1250.0, based on trading volumes and open interest. Notable options activity includes both bullish and bearish sentiments with varying strike prices and expiration dates. ASML, a leader in photolithography systems for semiconductor manufacturing, is currently trading at $884.0, down by -0.75%, with an RSI suggesting potential overbought conditions. Analysts from Susquehanna and Raymond James have issued positive ratings, with target prices ranging from $850 to $1100. The company's anticipated earnings release is in 72 days.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 3:45 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo for February 5th, 2024, provides a trade strategy for SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA, based on a proprietary formula considering price, volume, and options flow. It offers detailed analysis for each asset, suggesting potential breakouts or reversals. The memo also highlights the importance of upcoming data releases and the Market Clubhouse community's benefits, including live trading sessions and mentorship from a pro trader known as RIPS.

Portfolio Pulse from RIPS

February 05, 2024 | 3:45 pm

BRTX

BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares rose after presenting positive preliminary clinical data from a Phase 2 trial of BRTX-100 for chronic lumbar disc disease at the Orthopaedic Research Society 2024 Annual Meeting. The data showed a positive trend and no notable safety issues.

Portfolio Pulse from Erica Kollmann

February 05, 2024 | 3:42 pm

AAPL

NVDA

SSNLF

Samsung Electronics Co, led by Jay Y. Lee, was acquitted of stock manipulation charges, a significant legal victory allowing Lee to continue leading the company. This ruling comes as Samsung faces competition from Apple Inc in smartphones and SK Hynix Inc in AI, with plans to commercialize advanced chips by 2025 and 2027. The acquittal removes the threat of imprisonment for Lee, enabling him to focus on Samsung's challenges, including a downturn in the smartphone and memory chip markets. Nvidia Corp, a rival in the chip sector, saw its shares rise by 3.08% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

February 05, 2024 | 3:41 pm

EVBG

FDMT

Estée Lauder reported better-than-expected Q2 results and announced a restructuring program, leading to a 14% stock increase. Other stocks like 4D Molecular Therapeutics, Everbridge, and ON Semiconductor also saw significant gains due to positive news such as clinical trial data, acquisitions, and strong financial results.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 3:32 pm

AAPL

GOOG